Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

Timothy R. Wilson, Jane Fridlyand, Yibing Yan, Elicia Penuel, Luciana Burton, Emily Chan, Jing Peng, Eva Lin, Yulei Wang, Jeff Sosman, Antoni Ribas, Jiang Li, John Moffat, Daniel P. Sutherlin, Hartmut Koeppen, Mark Merchant, Richard Neve and Jeff Settleman ()
Additional contact information
Timothy R. Wilson: Research Oncology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Jane Fridlyand: Biostatastics, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Yibing Yan: Development Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Elicia Penuel: Development Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Luciana Burton: Development Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Emily Chan: Research Oncology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Jing Peng: Research Oncology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Eva Lin: Research Oncology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Yulei Wang: Development Sciences, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Jeff Sosman: Vanderbilt University Medical Center, 777 Preston Research Building, Nashville, Tennessee 37232, USA
Antoni Ribas: Jonsson Comprehensive Cancer Center, University of California Los Angeles, 9-954 Factor Building, 10833 Le Conte Avenue, Los Angeles, California 90095, USA
Jiang Li: Medical Developmental Biometrics Biostatistics, Roche Nutley, 340 Kingsland Street, Nutley, New Jersey 07110, USA
John Moffat: Biochemical and Cellular Pharmacology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Daniel P. Sutherlin: Discovery Chemistry, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Hartmut Koeppen: Research Pathology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Mark Merchant: Research Oncology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Richard Neve: Research Oncology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA
Jeff Settleman: Research Oncology, Genentech Inc., 1 DNA Way, South San Francisco, California 94080, USA

Nature, 2012, vol. 487, issue 7408, 505-509

Abstract: The efficacy of kinase inhibitors in treating cancer is limited by drug resistance; here it is shown that most human tumour cells can develop drug resistance through being exposed to one or more receptor tyrosine kinase ligands.

Date: 2012
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://www.nature.com/articles/nature11249 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:487:y:2012:i:7408:d:10.1038_nature11249

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature11249

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().